AAT Deficiency

(asked on 14th November 2018) - View Source

Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, when he plans a NHS service for alpha-1 to improve patients' access to coordinated multi-disciplinary clinical expertise, which was approved by the Department's Prescribed Specialised Services Advisory Group in March 2016, to commence.


Answered by
Caroline Dinenage Portrait
Caroline Dinenage
This question was answered on 21st November 2018

The Specialised Respiratory Clinical Reference Group (CRG) is maintaining an oversight of the need to develop a service specification and selection of providers to offer specialised expertise and management advice for patients diagnosed with alpha1 antitrypsin deficiency (AATD).

The CRG has recommended that NHS England wait until it is clear on the outcome of the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies evaluation of human alpha1-proteinase inhibitor for treating emphysema in adults with documented severe AATD [ID856] until this development is taken forward.

NICE has not yet published final guidance and recently consulted on its draft guidance. NICE’s evaluation committee is due to meet again to consider its recommendations in spring next year. This is to enable the company that makes the alpha1-proteinase inhibitor to prepare and submit additional information for consideration by the committee.

Reticulating Splines